Symbols / GERN Stock $1.39 -4.79% Geron Corporation

Healthcare • Biotechnology • United States • NMS
GERN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Harout Semerjian
Exch · Country NMS · United States
Market Cap 891.71M
Enterprise Value 701.38M
Income -67.31M
Sales 196.12M
FCF (ttm) -92.14M
Book/sh 0.34
Cash/sh 0.49
Employees 258
Insider 10d —
IPO Jul 31, 1996
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 19.86
PEG —
P/S 4.55
P/B 4.06
P/C —
EV/EBITDA -20.27
EV/Sales 3.58
Quick Ratio 4.85
Current Ratio 6.78
Debt/Eq 53.28
LT Debt/Eq —
EPS (ttm) -0.11
EPS next Y 0.07
EPS Growth —
Revenue Growth 30.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA -4.00%
ROE -27.07%
ROIC —
Gross Margin 65.19%
Oper. Margin -0.46%
Profit Margin -34.32%
Shs Outstand 641.52M
Shs Float 511.57M
Insider Own 0.08%
Instit Own 77.52%
Short Float 12.83%
Short Ratio 3.96
Short Interest 82.16M
52W High 2.01
vs 52W High -30.85%
52W Low 1.04
vs 52W Low 33.65%
Beta 0.68
Impl. Vol. 45.88%
Rel Volume 0.68
Avg Volume 18.45M
Volume 12.60M
Target (mean) $4.00
Tgt Median $4.00
Tgt Low $3.00
Tgt High $5.00
# Analysts 4
Recom Buy
Prev Close $1.46
Price $1.39
Change -4.79%
About

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.00
Mean price target
2. Current target
$1.39
Latest analyst target
3. DCF / Fair value
$-2.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.39
Low
$3.00
High
$5.00
Mean
$4.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-05 main Needham Buy → Buy $4
2025-05-08 down Scotiabank Sector Outperform → Sector Perform $2
2025-03-12 reit Needham Buy → Buy $5
2025-03-12 reit HC Wainwright & Co. Neutral → Neutral —
2025-02-27 main Scotiabank Sector Outperform → Sector Outperform $4
2025-02-27 main Stifel Buy → Buy $4
2025-02-27 main Barclays Overweight → Overweight $4
2025-02-27 main Needham Buy → Buy $5
2025-02-26 down HC Wainwright & Co. Buy → Neutral —
2025-02-18 main B. Riley Securities Buy → Buy $4
2025-01-13 main Needham Buy → Buy $7
2024-12-13 reit Needham Buy → Buy $6
2024-12-10 reit HC Wainwright & Co. Buy → Buy $9
2024-11-06 reit HC Wainwright & Co. Buy → Buy $8
2024-11-05 init HC Wainwright & Co. — → Buy $8
2024-10-16 init Scotiabank — → Sector Outperform $6
2024-09-09 init Leerink Partners — → Outperform $7
2024-08-09 reit Needham Buy → Buy $6
2024-07-26 reit Needham Buy → Buy $6
2024-06-11 init Barclays — → Overweight $9
News
RSS: Latest GERN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 SPIEGEL ROBERT J Director — 5,243 $1.49 $7,812
2026-02-18 ROBERTSON MICHELLE Chief Financial Officer — 9,855 $1.94 $19,119
2026-02-18 ROBERTSON MICHELLE Chief Financial Officer — 27,500 — —
2025-12-31 SPIEGEL ROBERT J Director — 5,918 $1.32 $7,812
2025-09-30 SPIEGEL ROBERT J Director — 5,702 $1.37 $7,812
2025-06-30 SPIEGEL ROBERT J Director — 5,540 $1.41 $7,811
2025-05-09 LAWLIS VIRGIL BRYAN JR. Director — 13,300 $1.18 $15,667
2025-03-31 SPIEGEL ROBERT J Director — 4,913 $1.59 $7,812
2025-02-27 SCARLETT JOHN A Chief Executive Officer — 12,500 $1.76 $22,062
2025-02-27 SAMUELS SCOTT ALAN Officer — 15,000 $1.61 $24,150
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
183.88
+138.83%
76.99
+32386.92%
0.24
-60.23%
0.60
Operating Revenue
223.37
+148.42%
89.92
+37839.66%
0.24
-60.23%
0.60
Cost Of Revenue
4.75
+277.79%
1.26
0.00
0.00
Reconciled Cost Of Revenue
4.75
+277.79%
1.26
0.00
0.00
Gross Profit
179.14
+136.52%
75.74
+31856.96%
0.24
-60.23%
0.60
Operating Expense
230.69
-7.53%
249.47
+28.47%
194.18
+39.55%
139.15
Research And Development
71.43
-31.14%
103.74
-17.04%
125.05
+30.91%
95.52
Selling General And Administration
159.26
+9.28%
145.73
+110.79%
69.14
+58.46%
43.63
General And Administrative Expense
—
145.73
+110.79%
69.14
+58.46%
43.63
Other Gand A
—
145.73
+110.79%
69.14
+58.46%
43.63
Total Expenses
235.43
-6.10%
250.73
+29.12%
194.18
+39.55%
139.15
Operating Income
-51.55
+70.33%
-173.73
+10.42%
-193.94
-39.98%
-138.55
Total Operating Income As Reported
-68.58
+60.52%
-173.73
+10.42%
-193.94
-39.98%
-138.55
EBITDA
-49.64
+67.94%
-154.85
+11.41%
-174.78
-30.29%
-134.15
Normalized EBITDA
-32.61
+78.71%
-153.14
+12.38%
-174.78
-30.29%
-134.15
Reconciled Depreciation
1.20
-1.39%
1.22
+18.20%
1.03
+19.01%
0.87
EBIT
-50.84
+67.42%
-156.07
+11.23%
-175.81
-30.22%
-135.02
Total Unusual Items
-17.03
-897.77%
-1.71
0.00
0.00
Total Unusual Items Excluding Goodwill
-17.03
-897.77%
-1.71
0.00
0.00
Special Income Charges
-17.03
-897.77%
-1.71
0.00
0.00
Other Special Charges
—
1.71
—
—
Restructuring And Mergern Acquisition
17.03
0.00
0.00
—
Net Income
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Pretax Income
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Net Non Operating Interest Income Expense
-14.54
-1418.22%
1.10
-88.79%
9.84
+326.05%
-4.35
Interest Expense Non Operating
32.66
+76.49%
18.50
+122.62%
8.31
+20.78%
6.88
Net Interest Income
-14.54
-1418.22%
1.10
-88.79%
9.84
+326.05%
-4.35
Interest Expense
32.66
+76.49%
18.50
+122.62%
8.31
+20.78%
6.88
Interest Income Non Operating
18.12
-7.60%
19.61
+8.02%
18.15
+617.75%
2.53
Interest Income
18.12
-7.60%
19.61
+8.02%
18.15
+617.75%
2.53
Other Income Expense
-17.41
-795.88%
-1.94
-8347.83%
-0.02
-102.30%
1.00
Other Non Operating Income Expenses
-0.38
-58.90%
-0.24
-926.09%
-0.02
-102.30%
1.00
Tax Rate For Calcs
0.00
-66.67%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.02
-232.59%
-0.01
0.00
0.00
Net Income Including Noncontrolling Interests
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Net Income From Continuing Operation Net Minority Interest
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Net Income From Continuing And Discontinued Operation
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Net Income Continuous Operations
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Normalized Income
-66.49
+61.54%
-172.87
+6.11%
-184.13
-29.76%
-141.90
Net Income Common Stockholders
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Diluted EPS
-0.13
+51.85%
-0.27
+15.62%
-0.32
+13.51%
-0.37
Basic EPS
-0.13
+51.85%
-0.27
+15.62%
-0.32
+13.51%
-0.37
Basic Average Shares
666.66
+3.19%
646.03
+13.21%
570.65
+49.86%
380.78
Diluted Average Shares
666.66
+3.19%
646.03
+13.21%
570.65
+49.86%
380.78
Diluted NI Availto Com Stockholders
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
570.54
-3.91%
593.78
+50.68%
394.08
+106.78%
190.57
Current Assets
520.27
+5.96%
490.99
+43.84%
341.35
+89.38%
180.25
Cash Cash Equivalents And Short Term Investments
357.92
-11.97%
406.57
+21.84%
333.70
+93.17%
172.75
Cash And Cash Equivalents
77.56
-1.84%
79.02
+12.84%
70.02
+23.18%
56.84
Other Short Term Investments
280.36
-14.41%
327.55
+24.22%
263.68
+127.50%
115.90
Receivables
39.23
+1.10%
38.80
+2244.35%
1.66
-47.36%
3.14
Accounts Receivable
36.99
+2.90%
35.95
0.00
—
Accrued Interest Receivable
2.24
-21.52%
2.85
+72.39%
1.66
-47.36%
3.14
Inventory
116.64
+201.28%
38.71
0.00
—
Raw Materials
8.93
+82.04%
4.90
—
—
Work In Process
91.97
+205.62%
30.09
—
—
Finished Goods
15.74
+323.46%
3.72
0.00
—
Prepaid Assets
—
—
—
—
Restricted Cash
1.88
+1.08%
1.86
+66.82%
1.11
+206.32%
0.36
Other Current Assets
4.61
-8.77%
5.05
+3.57%
4.88
+22.22%
3.99
Total Non Current Assets
50.27
-51.09%
102.79
+94.94%
52.73
+410.49%
10.33
Net PPE
3.04
-27.58%
4.19
-11.45%
4.73
-4.19%
4.94
Gross PPE
5.24
-11.02%
5.89
-1.27%
5.96
+2.19%
5.84
Accumulated Depreciation
-2.20
-29.88%
-1.70
-37.86%
-1.23
-37.39%
-0.90
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
2.15
-25.34%
2.88
-18.98%
3.56
-14.25%
4.15
Machinery Furniture Equipment
2.96
+2.81%
2.88
+26.62%
2.27
+46.27%
1.55
Leases
0.13
+0.00%
0.13
-4.44%
0.14
+0.00%
0.14
Investments And Advances
41.29
-56.32%
94.52
+118.30%
43.30
0.00
Non Current Prepaid Assets
—
—
—
5.39
Other Non Current Assets
5.95
+45.75%
4.08
-13.16%
4.70
-12.84%
5.39
Total Liabilities Net Minority Interest
344.67
+9.96%
313.46
+114.51%
146.13
+32.15%
110.58
Current Liabilities
111.54
+26.32%
88.30
-18.30%
108.07
+40.91%
76.69
Payables And Accrued Expenses
59.11
+37.13%
43.11
-7.24%
46.47
+7.34%
43.29
Payables
11.26
+30.97%
8.60
+39.51%
6.16
-39.54%
10.19
Accounts Payable
11.26
+30.97%
8.60
+39.51%
6.16
-39.54%
10.19
Current Accrued Expenses
47.85
+38.66%
34.51
-14.38%
40.31
+21.78%
33.10
Pensionand Other Post Retirement Benefit Plans Current
30.50
+33.71%
22.81
+65.77%
13.76
+19.29%
11.53
Current Debt And Capital Lease Obligation
1.00
+2.67%
0.97
-97.96%
47.84
+118.76%
21.87
Current Debt
—
—
46.89
+123.89%
20.95
Other Current Borrowings
—
—
46.89
+123.89%
20.95
Current Capital Lease Obligation
1.00
+2.67%
0.97
+2.63%
0.95
+2.59%
0.93
Current Deferred Liabilities
3.49
+235.84%
1.04
—
—
Current Deferred Revenue
3.49
+235.84%
1.04
—
—
Other Current Liabilities
17.45
-14.35%
20.37
—
—
Total Non Current Liabilities Net Minority Interest
233.13
+3.54%
225.16
+491.65%
38.06
+12.32%
33.88
Long Term Debt And Capital Lease Obligation
120.99
+0.21%
120.74
+217.27%
38.06
+12.32%
33.88
Long Term Debt
119.55
+0.90%
118.48
+238.01%
35.05
+16.02%
30.21
Long Term Capital Lease Obligation
1.45
-36.23%
2.27
-24.62%
3.01
-18.11%
3.67
Other Non Current Liabilities
112.13
+7.39%
104.42
—
—
Stockholders Equity
225.87
-19.42%
280.32
+13.06%
247.95
+209.94%
80.00
Common Stock Equity
225.87
-19.42%
280.32
+13.06%
247.95
+209.94%
80.00
Capital Stock
0.64
+5.61%
0.61
+11.19%
0.55
+39.74%
0.39
Common Stock
0.64
+5.61%
0.61
+11.19%
0.55
+39.74%
0.39
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
639.86
+5.52%
606.39
+11.28%
544.91
+39.63%
390.26
Ordinary Shares Number
639.86
+5.52%
606.39
+11.28%
544.91
+39.63%
390.26
Additional Paid In Capital
2,080.80
+1.41%
2,051.79
+11.21%
1,844.99
+23.54%
1,493.47
Retained Earnings
-1,855.84
-4.71%
-1,772.34
-10.93%
-1,597.77
-13.03%
-1,413.64
Gains Losses Not Affecting Retained Earnings
0.27
+3.07%
0.26
+41.08%
0.18
+184.47%
-0.22
Other Equity Adjustments
0.27
+3.07%
0.26
+41.08%
0.18
+184.47%
-0.22
Total Equity Gross Minority Interest
225.87
-19.42%
280.32
+13.06%
247.95
+209.94%
80.00
Total Capitalization
345.42
-13.38%
398.80
+40.92%
283.00
+156.78%
110.21
Working Capital
408.73
+1.50%
402.69
+72.62%
233.28
+125.28%
103.55
Invested Capital
345.42
-13.38%
398.80
+20.89%
329.89
+151.53%
131.16
Total Debt
121.99
+0.23%
121.72
+41.70%
85.90
+54.07%
55.75
Net Debt
41.99
+6.40%
39.46
+231.01%
11.92
—
Capital Lease Obligations
2.44
-24.54%
3.24
-18.08%
3.96
-13.95%
4.60
Net Tangible Assets
225.87
-19.42%
280.32
+13.06%
247.95
+209.94%
80.00
Tangible Book Value
225.87
-19.42%
280.32
+13.06%
247.95
+209.94%
80.00
Available For Sale Securities
—
94.52
+118.30%
43.30
—
Held To Maturity Securities
41.29
-56.32%
94.52
—
—
Interest Payable
3.11
+42.27%
2.19
+184.64%
0.77
+36.90%
0.56
Investmentin Financial Assets
41.29
-56.32%
94.52
+118.30%
43.30
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-111.04
+49.21%
-218.62
-30.33%
-167.74
-31.69%
-127.38
Cash Flow From Continuing Operating Activities
-111.04
+49.21%
-218.62
-30.33%
-167.74
-31.69%
-127.38
Net Income From Continuing Operations
-83.50
+52.17%
-174.57
+5.19%
-184.13
-29.76%
-141.90
Depreciation Amortization Depletion
1.20
-1.39%
1.22
+18.20%
1.03
+19.01%
0.87
Depreciation
1.20
-1.39%
1.22
+18.20%
1.03
+19.01%
0.87
Depreciation And Amortization
1.20
-1.39%
1.22
+18.20%
1.03
+19.01%
0.87
Other Non Cash Items
20.02
+794.90%
2.24
+105.61%
1.09
-18.01%
1.33
Pension And Employee Benefit Expense
—
5.34
0.00
0.00
Stock Based Compensation
26.75
-14.60%
31.32
+61.83%
19.35
+134.17%
8.27
Provisionand Write Offof Assets
-0.05
+80.08%
-0.25
0.00
0.00
Operating Gains Losses
—
1.71
—
—
Gain Loss On Investment Securities
—
—
—
—
Unrealized Gain Loss On Investment Securities
—
—
—
0.00
Change In Working Capital
-68.54
+2.92%
-70.60
-1265.16%
6.06
+20.53%
5.03
Change In Receivables
-0.38
+98.98%
-36.89
-2576.04%
1.49
+207.89%
-1.38
Changes In Account Receivables
-0.99
+97.22%
-35.70
0.00
0.00
Change In Inventory
-77.92
-105.21%
-37.97
0.00
0.00
Change In Prepaid Assets
-1.42
-420.99%
0.44
+328.35%
-0.19
+93.98%
-3.22
Change In Payables And Accrued Expense
18.45
+893.93%
-2.32
-173.10%
3.18
-53.04%
6.77
Change In Accrued Expense
15.79
+431.79%
-4.76
-166.02%
7.21
+120.70%
3.27
Change In Payable
2.66
+9.28%
2.44
+160.44%
-4.03
-215.02%
3.50
Change In Account Payable
2.66
+9.28%
2.44
+160.44%
-4.03
-215.02%
3.50
Change In Other Working Capital
7.69
-15.03%
9.05
+306.88%
2.22
-35.25%
3.44
Change In Other Current Liabilities
-14.96
-415.51%
-2.90
-353.28%
-0.64
-11.89%
-0.57
Investing Cash Flow
107.25
+201.17%
-106.00
+41.21%
-180.32
-390.53%
62.07
Cash Flow From Continuing Investing Activities
107.25
+201.17%
-106.00
+41.21%
-180.32
-390.53%
62.07
Net PPE Purchase And Sale
-0.05
+92.79%
-0.68
+18.07%
-0.83
-92.58%
-0.43
Purchase Of PPE
-0.05
+92.79%
-0.68
+18.07%
-0.83
-92.58%
-0.43
Capital Expenditure
-0.05
+92.79%
-0.68
+18.07%
-0.83
-92.58%
-0.43
Net Investment Purchase And Sale
107.30
+201.87%
-105.32
+41.32%
-179.49
-387.20%
62.50
Purchase Of Investment
-304.42
+36.17%
-476.93
-0.28%
-475.59
-84.33%
-258.01
Sale Of Investment
411.72
+10.79%
371.61
+25.50%
296.10
-7.61%
320.50
Net Business Purchase And Sale
—
—
—
—
Financing Cash Flow
2.27
-99.32%
334.37
-7.64%
362.02
+314.86%
87.26
Cash Flow From Continuing Financing Activities
2.27
-99.32%
334.37
-7.64%
362.02
+314.86%
87.26
Net Issuance Payments Of Debt
0.00
-100.00%
34.57
+16.38%
29.70
0.00
Issuance Of Debt
0.00
-100.00%
121.12
+307.81%
29.70
0.00
Repayment Of Debt
0.00
+100.00%
-86.55
0.00
0.00
Long Term Debt Issuance
0.00
-100.00%
121.12
+307.81%
29.70
0.00
Long Term Debt Payments
0.00
+100.00%
-86.55
0.00
0.00
Net Long Term Debt Issuance
0.00
-100.00%
34.57
+16.38%
29.70
0.00
Net Common Stock Issuance
0.00
-100.00%
140.73
-34.03%
213.34
+205.13%
69.92
Proceeds From Stock Option Exercised
2.27
-93.35%
34.08
-71.36%
118.98
+585.87%
17.35
Net Other Financing Charges
—
125.00
—
—
Changes In Cash
-1.52
-115.62%
9.75
-30.14%
13.96
-36.42%
21.95
Effect Of Exchange Rate Changes
0.09
+825.00%
-0.01
+55.56%
-0.03
-222.73%
0.02
Beginning Cash Position
80.88
+13.69%
71.14
+24.35%
57.21
+62.36%
35.23
End Cash Position
79.44
-1.78%
80.88
+13.69%
71.14
+24.35%
57.21
Free Cash Flow
-111.09
+49.34%
-219.30
-30.09%
-168.57
-31.89%
-127.81
Amortization Of Securities
-6.92
+28.52%
-9.68
+13.16%
-11.15
-1055.44%
-0.96
Common Stock Issuance
0.00
-100.00%
140.73
-34.03%
213.34
+205.13%
69.92
Earnings Losses From Equity Investments
—
—
—
—
Issuance Of Capital Stock
0.00
-100.00%
140.73
-34.03%
213.34
+205.13%
69.92
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category